Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Short-term Investments (2023 - 2025)

Historic Short-term Investments for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $190.2 million.

  • Beta Bionics' Short-term Investments changed N/A to $190.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.2 million, marking a year-over-year change of. This contributed to the annual value of $73.1 million for FY2024, which is 422.35% up from last year.
  • Per Beta Bionics' latest filing, its Short-term Investments stood at $190.2 million for Q3 2025.
  • Beta Bionics' Short-term Investments' 5-year high stood at $214.6 million during Q2 2025, with a 5-year trough of $70.2 million in Q4 2023.
  • For the 3-year period, Beta Bionics' Short-term Investments averaged around $147.4 million, with its median value being $189.0 million (2025).
  • The largest annual percentage gain for Beta Bionics' Short-term Investments in the last 5 years was 422.35% (2024), contrasted with its biggest fall of 422.35% (2024).
  • Beta Bionics' Short-term Investments (Quarter) stood at $70.2 million in 2023, then rose by 4.22% to $73.1 million in 2024, then skyrocketed by 160.04% to $190.2 million in 2025.
  • Its Short-term Investments stands at $190.2 million for Q3 2025, versus $214.6 million for Q2 2025 and $189.0 million for Q1 2025.